NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ancilia Biosciences

Ancilia Biosciences

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.anciliabio.com/

Last Round

Seed

Apr 6, 2026

Total Funding Raised

$7.73M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ancilia Biosciences is a biotechnology company developing a new class of live biotherapeutics and other microbial products with immunity to key viral pathogens by harnessing the natural power of CRISPR.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

live biotherapeuticsLBPmicrobiome therapeuticsCRISPRphage resistancebacteriophagesynthetic biologysynbiocomputational viromebioinformaticsdrug discoverymicrobial engineeringprecision medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ancilia Biosciences Comparables

Compare Ancilia Biosciences with similar companies based on industry and business-model similarity.

Ancilia Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Ancilia Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 6, 2026
GrantOct 23, 2024
GrantOct 23, 2024
SeedJul 17, 2024
GrantAug 1, 2021

Key People

Founding team and executive leadership

David Páez-Espino

Chief Technology Officer, Co-Founder

Founding Team

Alexandra Sakatos

Co-Founder CEO

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2026

    $10M Seed Round raised.

  • Oct 23, 2024

    $274K grant received from NIH RADx and NIDDK.

Ancilia Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ancilia Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ancilia Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range20
Year Founded2019
Last FundingApr 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.